Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Phase 2

Completed

Conditions: Metastatic Melanoma
Metastatic Kidney Cancer

Interventions: Drug: Natural Killer (NK) Lymphocytes
Biological: IL-2
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2006-05-22

Last Posted Date: 2012-11-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT00328861

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

Phase 3

Completed

Conditions: Clear Cell Renal Cell Carcinoma
Stage I Renal Cell Cancer AJCC v6 and v7
Stage II Renal Cell Cancer AJCC v7
Stage III Renal Cell Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Other: Placebo
Other: Quality-of-Life Assessment
Drug: Sorafenib Tosylate
Drug: Sunitinib Malate

First Posted Date: 2006-05-17

Last Posted Date: 2022-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1943

Registration Number: NCT00326898

Locations: 🇺🇸
Grant Medical Center, Columbus, Ohio, United States
🇺🇸
Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States

and more 974 locations

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Cetuximab
Drug: BAY 43-9006

First Posted Date: 2006-05-17

Last Posted Date: 2017-07-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00326495

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Phase 2

Terminated

Conditions: Spinal Cord Neurofibroma
Plexiform Neurofibroma
Neurofibromatosis Type 1

Interventions: Drug: Cediranib Maleate

First Posted Date: 2006-05-17

Last Posted Date: 2017-08-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00326872

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Howard University Hospital, Washington, D.C., District of Columbia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase 1

Completed

Conditions: Childhood Central Nervous System Germ Cell Tumor
Recurrent Childhood Subependymal Giant Cell Astrocytoma
Childhood Grade II Meningioma
Childhood Infratentorial Ependymoma
Childhood Spinal Cord Neoplasm
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Ependymoma
Recurrent Childhood Medulloblastoma
Childhood Cerebral Astrocytoma

Interventions: Drug: Cediranib Maleate

First Posted Date: 2006-05-17

Last Posted Date: 2016-03-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00326664

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 8 locations

Cinacalcet to Treat Familial Primary Hyperparathyroidism

Phase 3

Completed

Conditions: Hypercalcemia
Familial Primary Hyperparathyroidism

First Posted Date: 2006-05-12

Last Posted Date: 2017-07-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 25

Registration Number: NCT00325104

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: vorinostat
Other: pharmacological study

First Posted Date: 2006-05-11

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00324480

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer

Phase 1

Terminated

Conditions: Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: vorinostat
Drug: isotretinoin

First Posted Date: 2006-05-11

Last Posted Date: 2021-02-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT00324740

Locations: 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
🇺🇸
Weill Medical College of Cornell University, New York, New York, United States

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Phase 3

Completed

Conditions: Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
Stage IIA Lung Non-Small Cell Carcinoma AJCC v7

Interventions: Drug: Cisplatin
Biological: Bevacizumab
Drug: Docetaxel
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Pemetrexed Disodium
Other: Questionnaire Administration
Drug: Vinorelbine Tartrate

First Posted Date: 2006-05-11

Last Posted Date: 2025-03-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1501

Registration Number: NCT00324805

Locations: 🇺🇸
Bayhealth Hospital Kent Campus, Dover, Delaware, United States
🇺🇸
Beebe Medical Center, Lewes, Delaware, United States
🇺🇸
Phoebe Putney Memorial Hospital, Albany, Georgia, United States

and more 1157 locations

Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase 1

Completed

Conditions: Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer
Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer

Interventions: Drug: vorinostat
Drug: bevacizumab

First Posted Date: 2006-05-11

Last Posted Date: 2016-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00324870

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Peninsula Oncology and Hematology PA, Salisbury, Maryland, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy